This page can be referred to using the following tiny url: http://tinyurl.com/nfdj6dr
National Institute for Health and Clinical Excellence (NICE)
This guidance replaces NICE technology appraisal guidance 271 (published January 2013). TA271 did not recommend fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema considered insufficiently responsive to available therapies. The updated guidance recommends fluocinolone acetonide intravitreal implant as an option for treating chronic diabetic macular oedema that is insufficiently responsive to available therapies only if the implant is to be used in an eye with an intraocular (pseudophakic) lens and the manufacturer provides fluocinolone acetonide intravitreal implant with the discount agreed in the patient access scheme.
National Institute for Health and Clinical Excellence (NICE). (2013) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) [Online]. Available from: http://www.thehealthwell.info/node/668169 [Accessed: 20th February 2017].
Altmetrics are currently not available for this resource.